Why AI matters at this scale

The UW Carbone Cancer Center is a large, NCI-designated comprehensive cancer center embedded within a major academic medical system. With over 1,000 employees and decades of deep clinical and research data, it operates at a scale where manual analysis of complex oncology datasets—from genomics and medical imaging to electronic health records (EHR)—becomes a bottleneck. AI and machine learning are not just incremental improvements but essential tools to parse this data deluge. At this size, the center has the critical mass of data, technical talent, and institutional funding (e.g., from NIH grants) to justify strategic AI investments. These technologies can transform core missions: accelerating basic discovery, improving the efficiency and precision of clinical trials, and ultimately personalizing patient care. For an organization of this magnitude, failing to leverage AI risks falling behind in the competitive landscape of cancer research and diminishing its impact on patient outcomes.

Concrete AI Opportunities with ROI

1. AI-Powered Biomarker Discovery: By applying machine learning to integrated multi-omics data (genomics, proteomics) and clinical outcomes, researchers can identify novel biomarkers for early detection and prognosis. ROI: Faster discovery cycles can lead to new intellectual property, more competitive grant funding, and accelerated therapeutic development. 2. Automated Clinical Trial Matching: Manual screening of EHRs for trial eligibility is slow and error-prone. Natural language processing (NLP) models can automatically parse clinical notes and match patients to open trials. ROI: Dramatically increased patient recruitment rates (potentially 30-50% faster), higher trial enrollment, and reduced operational costs per enrolled patient. 3. Intelligent Research Data Management: An AI-augmented research data platform can automate data curation, harmonization, and provisioning from disparate sources (EHR, biobanks, imaging archives). ROI: Significant reduction in data preparation time for researchers (from weeks to days), increasing research productivity and allowing scientists to focus on analysis rather than data wrangling.

Deployment Risks Specific to This Size Band

Organizations in the 1,001–5,000 employee range face unique scaling challenges. Integration Complexity: The cancer center likely uses a mix of legacy systems, modern EHRs (like Epic), and specialized research software. Integrating AI tools across these platforms without disrupting clinical or research workflows is a major technical and change management hurdle. Data Governance at Scale: With vast amounts of sensitive patient data, establishing unified, compliant data access policies and secure computing environments (e.g., HIPAA-compliant cloud) for AI development requires significant upfront investment and cross-departmental coordination. Talent Retention: Competing with private industry for top AI/ML talent is difficult. The center must create compelling career paths and project opportunities to attract and retain data scientists and engineers. Funding Sustainability: While grant funding can kickstart AI projects, transitioning successful pilots into sustained, budgeted operational programs requires proving long-term value to institutional leadership, a process that can be slow in large academic settings.